ALX Oncology
Verified Intelalx oncology is a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer
alx oncology is a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the cd47 checkpoint pathway and bridge the innate and adaptive immune system. alx oncology’s lead product candidate, evorpacept (also known as alx148), is a next generation cd47 blocking therapeutic that combines a high-affinity cd47 binding domain with an inactivated, proprietary fc domain. evorpacept has demonstrated promising clinical responses across a range of hematologic and solid malignancies in combination with a number of leading anti-cancer agents.
Corporate Firmographics
Entity classification and operating profile
- Industry
- Biotechnology Research
- Company Type
- Public Company
- Founded
- 2015
- Employee Bracket
- 11-50
- Estimated Revenue Range
- $5,000,000 – $10,000,000
Geographic Coordinates
Headquarters address and regional territory
- Street Address
- 323 allerton ave
- City
- South San Francisco
- Region / State
- california
- Postal Code
- 94080
- Country
- United States
Core Competencies & Specialties
Synthesized domain expertise tags
Digital Presence & Footprint
Verified domains, socials, and directory profiles
Frequently Asked Questions
Verified business inquiries and firmographic telemetry for ALX Oncology.